Lupin Ltd

Lupin announced that the 43th Annual General Meeting(AGM) of the company will be held on 11 August 2025.Powered by Capital Market - Live

Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialization of Lupin's biosimilar Certolizumab Pegol, across multiple markets globally. This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide. Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada. Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of USD 10 million upon execution of the agreement and total development and regulatory milestone payments up to USD 50 million. The profits from the defined markets will be shared between the two companies. Powered by Capital Market - Live

Under the terms of the agreement, Lupin will be responsible for the development, manufacturing, and supply of the product within the agreed territories. Zentiva will handle commercialization activities across Europe and the CIS markets, leveraging its extensive commercial infrastructure and regulatory expertise in the region. Lupin will retain commercialization rights in other regions, including the USA and Canada. As part of the deal, Zentiva will make a non-refundable payment of up to USD 50 million, tied to regulatory milestones. This includes an upfront payment of $10 million upon execution of the agreement. Both companies will jointly invest in the development of the biosimilar, and profits from defined markets will be shared between the two parties. Zentiva, k.s. is a leading pharmaceutical company delivering affordable, high-quality medicines to over 100 million people in more than 30 countries, primarily across Europe. Lupin stated that this partnership with Zentiva aims to expand its market reach and provide high-quality and cost-effective biosimilars to patients worldwide. The company also clarified that the transaction does not involve any acquisition and Zentiva is not a related party. None of the promoters, promoter group, or group companies have any financial or other interest in the arrangement. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 0.43% to Rs 1,930 on the BSE today. Powered by Capital Market - Live

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent' Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent') had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today. Powered by Capital Market - Live

The product is a generic equivalent of Lotemax SM Ophthalmic Gel, 0.38%, marketed by Bausch & Lomb Inc. Lupin is the exclusive first-to-file applicant for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax' SM) had estimated annual sales of $29 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.85% to Rs 1,978.05 on the BSE.Powered by Capital Market - Live

Lupin announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare  (LCH), into a wholly owned subsidiary, effective 01 July 2025. This initiative aligns with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing self care market. Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac', Beplex Forte', Corcium' and Aptivate'. Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth. Powered by Capital Market - Live

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. Loteprednol Etabonate Ophthalmic Gel, 0.38% is bioequivalent to Lotemax' SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax' SM) had an estimated annual sale of USD 29 million in the U.S. (IQVIA MAT May 2025). Powered by Capital Market - Live

Lupin has today, 30 June 2025, executed a Business Transfer Agreement (BTA) for transfer of its Over-the-Counter Consumer Healthcare Business (OTC Business) to LUPINLIFE Consumer Healthcare (LCHL), a wholly owned subsidiary of the Company, on a slump sale basis. In terms of the BTA, the said transaction has been completed, and transfer of OTC Business will be effective from 01 July 2025.Powered by Capital Market - Live

Prucalopride Tablets are the bioequivalent of Motegrity' Tablets, developed by Takeda Pharmaceuticals U.S.A., Inc. The medication is indicated for the treatment of chronic idiopathic constipation (CIC) in adult patients. According to IQVIA MAT data for April 2025, the reference drug Motegrity' recorded annual sales of approximately $184 million in the U.S. market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.11% to Rs 1,913.70 on the BSE. Powered by Capital Market - Live